Status:
COMPLETED
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
Lead Sponsor:
Pfizer
Conditions:
Prostatic Hyperplasia
Eligibility:
MALE
40+ years
Phase:
PHASE2
Brief Summary
This is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.
Eligibility Criteria
Inclusion
- Male subjects, aged 40 years and above, with documented LUTS with an International Prostate Symptom Score (IPSS) ≥13.
- Clinical diagnosis of BPH
- Qmax 5 to 15 ml/sec with a voided volume of ≥150 ml
- Urodynamically defined bladder outlet obstruction
Exclusion
- prostate cancer
- Post-void residual urine volume \>200 ml
- Documented UTI
- History of relevant urological surgery
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00408954
Start Date
March 1 2007
End Date
June 1 2008
Last Update
November 23 2010
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brno, Czechia, 612 00
2
Pfizer Investigational Site
Hradec Králové, Czechia, 500 02
3
Pfizer Investigational Site
Olomouc, Czechia, 775 20
4
Pfizer Investigational Site
Ústí nad Labem, Czechia, 401 13